In this video, health-care analyst David Williamson discusses Peregrine Pharmaceuticals' announcement and stock pop from completing enrollment of a phase 1 trial for its lead drug candidate bavituximab in breast cancer. Bavituximab has endured a lot of (clinical) trials and tribulations, including in NSCLC and pancreatic cancer, and this video puts today's news into perspective with the larger picture investors need to know.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The company completes enrollment for a bavituximab breast cancer trial.
David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.
The Motley Fool recommends Celgene. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Celgene
CELG
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead?
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Is Oscar Health Stock Still a Buy?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.